Digiferruginol

Digiferruginol

SCHEMBL23199057

O=C1c2ccccc2C(=O)c2c1ccc(CO)c2O

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 11/20 0.69
MAPT P10636 6/20 0.62
MEN1 O00255 4/20 0.62
KMT2A Q03164 4/20 0.62
MCL1 Q07820 3/20 0.62
ALDH1A1 P00352 3/20 0.62
BCL2 P10415 2/20 0.62
MAPK1 P28482 2/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
MAOA P21397 2/20 0.62
KDM4E B2RXH2 1/20 0.62
CYP3A4 P08684 1/20 0.62
HPGD P15428 1/20 0.62
ALOX15 P16050 1/20 0.62
ALOX12 P18054 1/20 0.62
APEX1 P27695 1/20 0.62
RECQL P46063 1/20 0.62
DAPK1 P53355 1/20 0.62
CYP1B1 Q16678 1/20 0.62
HSD17B10 Q99714 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Digiferruginol SCHEMBL30614617 1.00 ELANE (0.69) ELANEMAPTMEN1KMT2AMCL1
SCHEMBL11299000 0.91 ELANE (0.54) ELANEMAPTMEN1KMT2AMCL1
SCHEMBL11297406 0.89 ELANE (0.53) ELANEMAPTMEN1KMT2AMCL1
SCHEMBL28758865 0.86 ELANE (0.69) ELANEMAPTMEN1KMT2AMCL1
SCHEMBL31256477 0.81 ELANE (0.68) ELANEMAPTMEN1KMT2AMCL1
SCHEMBL2396651 0.81 ELANE (0.53) ELANEMAPTMEN1KMT2AMCL1
SCHEMBL2398142 0.81 ELANE (0.50) ELANEMAPTMEN1KMT2AMCL1
SCHEMBL3111027 0.81 MEN1 (0.62) ELANEMAPTMEN1KMT2AMCL1
SCHEMBL436684 0.81 BCL2 (0.64) ELANEMAPTMEN1KMT2AMCL1
SCHEMBL2396782 0.81 ELANE (0.50) ELANEMAPTMEN1KMT2AMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3943085-A2 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION ETH Zurich (CH) 2022-01-26 EP claimed
US-20210186947-A1 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION ETH ZURICH (CH) 2021-06-24 US claimed
EP-3801507-A2 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION ETH Zurich (CH) 2021-04-14 EP claimed
US-20250197798-A1 METHOD OF CULTIVATING AND EXTRACTING CALLUS OF DAMNACANTHUS MAJOR AND COSMETIC COMPOSITION COMPRISING DAMNACANTHUS MAJOR CALLUS PREPARED BY USING THE SAME UCL CO., LTD. (KR) 2025-06-19 US disclosed
WO-2024189607-A1 METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT DIDENKO KIRILL (MX) 2024-09-19 WO disclosed
EP-3943085-A2 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION ETH Zurich (CH) 2022-01-26 EP disclosed
US-20210186947-A1 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION ETH ZURICH (CH) 2021-06-24 US disclosed
CN-109069563-A For treating and/or preventing Madagascar's Ha Lunjiana leaf extract of acne 化工产品开发公司SEPPIC 2018-12-21 CN disclosed
CN-108379454-A Treat the composition of gout 朝阳丛氏传统医药科学研究所 2018-08-10 CN disclosed
CN-102961473-B Preparation method of Hedyotis diffusa Willd. anti-cancer active component NIU YU 2014-08-06 CN disclosed
CN-102961473-A Preparation method of Hedyotis diffusa Willd. anti-cancer active component NIU YU 2013-03-13 CN disclosed
CN-101966243-A Method for preparing total anthraquinones of Indian damnacanthus herb NANJING ZELANG AGRI DEV CO LTD 2011-02-09 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210186947-A1 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION TOMM70, TOMM34, TIMM50 ELANE 4808/4885MAPT 2071/4885MEN1 2055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.